Gastric Ulcer
2
Pipeline Programs
3
Companies
4
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
3 programs1
Esomeprazole 40 mgPhase 31 trial
Nexium Capsules Helicobacter Pylori Specific Clinical Experience InvestigationN/A1 trial
Nexium Capsules LDA Specific Clinical Experience InvestigationN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TakedaTAK-438
AstraZenecaEsomeprazole 40 mg
AstraZenecaNexium Capsules LDA Specific Clinical Experience Investigation
AstraZenecaNexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
Clinical Trials (4)
Total enrollment: 5,640 patients across 4 trials
Efficacy of TAK-438 Compared to AG-1749 (Lansoprazole) in the Treatment of Gastric Ulcer
Start: Nov 2011Est. completion: Dec 2012482 patients
Phase 3Completed
Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)
Start: Feb 2007Est. completion: Aug 20082,426 patients
Phase 3Completed
Nexium Capsules LDA Specific Clinical Experience Investigation
Start: Jan 2013Est. completion: Mar 20172,363 patients
N/ACompleted
NCT01435525AstraZenecaNexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
Nexium Capsules Helicobacter Pylori Specific Clinical Experience Investigation
Start: Sep 2011Est. completion: Mar 2014369 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space